
    
      Participants who have completed participation in a Dermira- or Lilly-sponsored lebrikizumab
      study (parent study), DRM06-AD04, DRM06-AD05, DRM06-AD06, DRM06-AD17 or DRM06- AD18, will be
      offered the opportunity to enroll in this study. Participants may either be blinded or not
      blinded, depending on their parent study assignment.

      This study will also be open to an additional approximately 100 participants in the United
      States (addendum) who have not completed participation in a Dermira- or Lilly-sponsored
      lebrikizumab study. Treatment will not be blinded.
    
  